🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 22 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 25/07/2019 | 172,22 | 172,51 | 169,02 | 169,56 | -2,18% | 2,03% | 1.784.000 |
| 24/07/2019 | 175,00 | 175,00 | 172,31 | 173,34 | -1,08% | 1,54% | 1.135.700 |
| 23/07/2019 | 174,43 | 176,36 | 173,40 | 175,24 | +0,67% | 1,70% | 828.400 |
| 22/07/2019 | 173,34 | 174,57 | 172,41 | 174,08 | -0,03% | 1,25% | 1.121.000 |
| 19/07/2019 | 179,15 | 179,15 | 174,05 | 174,13 | -2,22% | 2,85% | 1.121.600 |
| 18/07/2019 | 176,92 | 178,58 | 176,38 | 178,09 | +0,54% | 1,24% | 853.500 |
| 17/07/2019 | 176,93 | 179,24 | 176,33 | 177,14 | +0,56% | 1,64% | 773.100 |
| 16/07/2019 | 176,47 | 177,93 | 175,58 | 176,16 | -0,12% | 1,33% | 620.000 |
| 15/07/2019 | 176,16 | 178,08 | 174,70 | 176,37 | +0,33% | 1,92% | 1.055.300 |
| 12/07/2019 | 176,06 | 176,27 | 173,95 | 175,79 | -0,12% | 1,32% | 1.004.000 |
| 11/07/2019 | 178,81 | 178,86 | 172,74 | 176,01 | -1,54% | 3,42% | 1.258.100 |
| 10/07/2019 | 179,00 | 179,75 | 175,53 | 178,76 | +0,17% | 2,36% | 766.600 |
| 09/07/2019 | 175,62 | 178,63 | 174,78 | 178,46 | +0,97% | 2,19% | 714.700 |
| 08/07/2019 | 177,76 | 177,76 | 174,18 | 176,75 | -0,89% | 2,01% | 818.900 |
| 05/07/2019 | 179,45 | 183,24 | 177,41 | 178,34 | -2,68% | 3,25% | 878.900 |
| 03/07/2019 | 180,25 | 183,45 | 178,54 | 183,26 | +2,08% | 2,72% | 571.600 |
| 02/07/2019 | 181,54 | 181,54 | 178,88 | 179,53 | -1,27% | 1,47% | 819.600 |
| 01/07/2019 | 185,07 | 185,14 | 180,81 | 181,84 | -0,84% | 2,34% | 1.111.500 |
| 28/06/2019 | 179,74 | 184,99 | 178,75 | 183,38 | +2,69% | 3,47% | 1.604.900 |
| 27/06/2019 | 178,00 | 179,24 | 176,68 | 178,58 | +0,52% | 1,44% | 731.500 |
| 26/06/2019 | 180,11 | 181,03 | 177,13 | 177,66 | -1,38% | 2,17% | 768.700 |
| 25/06/2019 | 181,64 | 183,10 | 179,49 | 180,15 | -0,48% | 1,99% | 960.100 |
| 24/06/2019 | 184,56 | 184,98 | 180,55 | 181,02 | -1,60% | 2,40% | 764.000 |
| 21/06/2019 | 183,34 | 184,45 | 180,76 | 183,97 | +0,99% | 2,01% | 1.844.600 |
| 20/06/2019 | 183,52 | 186,33 | 181,21 | 182,17 | +0,23% | 2,79% | 1.217.700 |
| 19/06/2019 | 178,52 | 182,14 | 177,00 | 181,75 | +2,14% | 2,88% | 1.535.400 |
| 18/06/2019 | 175,97 | 178,90 | 174,80 | 177,94 | +2,39% | 2,33% | 1.521.400 |
| 17/06/2019 | 171,17 | 174,14 | 171,17 | 173,78 | +2,09% | 1,74% | 955.600 |
| 14/06/2019 | 168,90 | 170,99 | 167,94 | 170,22 | +0,79% | 1,81% | 806.100 |
| 13/06/2019 | 171,17 | 171,95 | 167,84 | 168,89 | -1,02% | 2,40% | 951.600 |